Table 2 Results of multivariable Cox analyses for HCC recurrence and overall death.

From: Cumulative exposure to tacrolimus during early period after liver transplantation does not affect the recurrence of hepatocellular carcinoma

Variables

HCC recurrence a

Overall death

HR

95% CI

P

HR

95% CI

P

Group by CET 90 days

 Conventional

1.00

  

1.00

  

 Aggressive minimization

1.23

0.50–3.03

0.652

5.64

2.18–14.63

 < 0.001

 Minimization

0.97

0.53–1.76

0.918

1.13

0.59–2.17

0.719

 High exposure

0.93

0.50–1.75

0.833

1.67

0.94–2.95

0.081

Age

0.96

0.93–1.00

0.041

1.05

1.01–1.09

0.008

BMI

0.92

0.85–1.00

0.038

0.91

0.85–0.98

0.014

Pre-transplant MELD

0.95

0.90–1.00

0.042

   

Deceased vs. living donor

   

0.50

0.30–0.84

0.008

Log AFP

1.16

1.02–1.33

0.028

1.19

1.05–1.34

0.006

Bridging treatment

 Locoregional

1.00

  

1.00

  

 None

0.22

0.09–0.57

0.002

0.79

0.42–1.46

0.449

 Systemic or radiotherapy

2.27

1.29–3.98

0.004

3.55

1.93–6.55

 < 0.001

Viable tumor number

1.07

1.01–1.12

0.014

1.05

1.00–1.10

0.064

Maximum tumor size

1.14

1.01–1.28

0.033

   

Microvascular invasion

2.26

1.31–3.88

0.003

   

Satellite nodule

1.83

1.02–3.27

0.043

4.57

2.59–8.06

 < 0.001

Use of mTOR inhibitor

   

0.26

0.12–0.57

0.001

Biopsy proven rejection within 3 months

   

2.55

1.12–5.84

0.026

  1. Covariates with P < 0.10 in univariable models were included in multivariable models.
  2. Only variables that were significant in the multivariable model were demonstrated except CET 90 days group. The full results are provided in the Supplementary Material (Tables S5, S6).
  3. AFP alpha-feto protein, CET cumulative exposure to tacrolimus, HCC hepatocellular carcinoma, MELD model for end-stage liver disease, PIVKA II protein induced by vitamin K absence or antagonist-II.
  4. aMultivariable analyses for HCC recurrence were performed, treating non-HCC death as a competing risk.
Back to article page